Qube Research & Technologies (QRT)’s Madrigal Pharmaceuticals MDGL Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,588	Closed	-$1.19M	–	3919
2025 Q3	$1.19M	Sell	2,588 -1,256	-33%	-$469K	﹤0.01%	2444
2025 Q2	$1.16M	Buy	+3,844	New	+$1.15M	﹤0.01%	2403
2024 Q2	–	Sell	-1,158	Closed	-$309K	–	4377
2024 Q1	$309K	Buy	1,158 +1,125	+3,409%	+$265K	﹤0.01%	2793
2023 Q4	$7.64K	Buy	+33	New	+$5.78K	﹤0.01%	3649
2022 Q3	–	Sell	-10,327	Closed	-$739K	–	2804
2022 Q2	$739K	Buy	+10,327	New	+$759K	0.01%	1238
2021 Q3	–	Sell	-6,364	Closed	-$620K	–	2555
2021 Q2	$620K	Buy	6,364 +2,473	+64%	+$293K	0.01%	1170
2021 Q1	$455K	Buy	+3,891	New	+$454K	0.01%	1234
2020 Q4	–	Sell	-7,093	Closed	-$842K	–	2046
2020 Q3	$842K	Buy	7,093 +5,243	+283%	+$569K	0.01%	861
2020 Q2	$210K	Buy	+1,850	New	+$182K	﹤0.01%	1421

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT)'s MDGL Position: Q4 2025 in Review

Qube Research & Technologies (QRT) sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 2,588 shares — an estimated $1.19M sold.

Qube Research & Technologies (QRT) first reported a position in MDGL in Q2 2020 and held it in 9 quarters. The position peaked at $1.19M in Q3 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

Qube Research & Technologies (QRT) reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 2,588 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $1.19M.
Qube Research & Technologies (QRT) first reported a position in Madrigal Pharmaceuticals in Q2 2020 and held it in 9 quarters.
Qube Research & Technologies (QRT)'s Madrigal Pharmaceuticals position peaked at $1.19M in Q3 2025.
387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2025, filed 17 Feb 2026.